Frontiers in Neuroscience (Oct 2022)

Retinal nerve fiber layer in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

  • Bryan M. Wong,
  • Bryan M. Wong,
  • Christopher Hudson,
  • Christopher Hudson,
  • Emily Snook,
  • Faryan Tayyari,
  • Faryan Tayyari,
  • Hyejung Jung,
  • Malcolm A. Binns,
  • Malcolm A. Binns,
  • Saba Samet,
  • Richard W. Cheng,
  • Carmen Balian,
  • Carmen Balian,
  • Efrem D. Mandelcorn,
  • Efrem D. Mandelcorn,
  • Edward Margolin,
  • Edward Margolin,
  • Elizabeth Finger,
  • Sandra E. Black,
  • Sandra E. Black,
  • David F. Tang-Wai,
  • David F. Tang-Wai,
  • Lorne Zinman,
  • Lorne Zinman,
  • Brian Tan,
  • Wendy Lou,
  • Mario Masellis,
  • Mario Masellis,
  • Agessandro Abrahao,
  • Agessandro Abrahao,
  • Andrew Frank,
  • Derek Beaton,
  • Kelly M. Sunderland,
  • Stephen R. Arnott,
  • ONDRI Investigators,
  • Maria Carmela Tartaglia,
  • Maria Carmela Tartaglia,
  • Wendy V. Hatch,
  • Wendy V. Hatch,
  • Sabrina Adamo,
  • Stephen Arnott,
  • Rob Bartha,
  • Derek Beaton,
  • Courtney Berezuk,
  • Alanna Black,
  • Alisia Bonnick,
  • David Breen,
  • Don Brien,
  • Susan Bronskill,
  • Dennis Bulman,
  • Leanne Casaubon,
  • Ying Chen,
  • Marvin Chum,
  • Brian Coe,
  • Ben Cornish,
  • Jane Lawrence Dewar,
  • Roger A. Dixon,
  • Sherif El-Defrawy,
  • Sali M.K. Farhan,
  • Frederico Faria,
  • Julia Fraser,
  • Mahdi Ghani,
  • Barry Greenberg,
  • Hassan Haddad,
  • Wendy Hatch,
  • Melissa Holmes,
  • Chris Hudson,
  • Peter Kleinstiver,
  • Donna Kwan,
  • Elena Leontieva,
  • Brian Levine,
  • Wendy Lou,
  • Efrem D. Mandelcorn,
  • Ed Margolin,
  • Connie Marras,
  • Bill McIlroy,
  • Paula McLaughlin,
  • Manuel Montero Odasso,
  • Doug Munoz,
  • David Munoz,
  • Nuwan Nanayakkara,
  • JB Orange,
  • Miracle Ozzoude,
  • Alicia Peltsch,
  • Pradeep Raamana,
  • Joel Ramirez,
  • Natalie Rashkovan,
  • Angela Roberts,
  • Yanina Sarquis Adamson,
  • Christopher Scott,
  • Michael Strong,
  • Stephen Strothers,
  • Sujeevini Sujanthan,
  • Kelly M. Sunderland,
  • Sean Symons,
  • Faryan Tayyari,
  • Athena Theyers,
  • Angela Troyer,
  • Abiramy Uthirakumaran,
  • Karen Van Ooteghem,
  • John Woulfe,
  • Mojdeh Zamyadi,
  • Guangyong (GY) Zou

DOI
https://doi.org/10.3389/fnins.2022.964715
Journal volume & issue
Vol. 16

Abstract

Read online

PurposeTauopathy and transactive response DNA binding protein 43 (TDP-43) proteinopathy are associated with neurodegenerative diseases. These proteinopathies are difficult to detect in vivo. This study examined if spectral-domain optical coherence tomography (SD-OCT) can differentiate in vivo the difference in peripapillary retinal nerve fibre layer (pRNFL) thickness and macular retinal thickness between participants with presumed tauopathy (progressive supranuclear palsy) and those with presumed TDP-43 proteinopathy (amyotrophic lateral sclerosis and semantic variant primary progressive aphasia).Study designProspective, multi-centre, observational study.Materials and methodspRNFL and macular SD-OCT images were acquired in both eyes of each participant using Heidelberg Spectralis SD-OCT. Global and pRNFL thickness in 6 sectors were analyzed, as well as macular thickness in a central 1 mm diameter zone and 4 surrounding sectors. Linear mixed model methods adjusting for baseline differences between groups were used to compare the two groups with respect to pRNFL and macular thickness.ResultsA significant difference was found in mean pRNFL thickness between groups, with the TDP-43 group (n = 28 eyes) having a significantly thinner pRNFL in the temporal sector than the tauopathy group (n = 9 eyes; mean difference = 15.46 μm, SE = 6.98, p = 0.046), which was not significant after adjusting for multiple comparisons. No other significant differences were found between groups for pRNFL or macular thickness.ConclusionThe finding that the temporal pRNFL in the TDP-43 group was on average 15.46 μm thinner could potentially have clinical significance. Future work with larger sample sizes, longitudinal studies, and at the level of retinal sublayers will help to determine the utility of SD-OCT to differentiate between these two proteinopathies.

Keywords